Goshima E, Yasuda K, Fuwa Y, Adachi K, Minamori Y, Murase H, Murayama M, Yamakita N, Miura K
Nihon Naibunpi Gakkai Zasshi. 1987 May 20;63(5):675-94. doi: 10.1507/endocrine1927.63.5_675.
Pharmacokinetics of prednisolone (PSL) was investigated in 10 patients treated with long-term intermittent regimen of PSL administration, 4 consecutive days administration a week. In 8 patients (group I; 3 of nephrotic syndrome, 2 of SLE, and each of Crohn's disease, aortitis syndrome, and hemolytic anemia), PSL was initially administered daily until the therapeutic effects were achieved (daily period), and this was followed by consecutive 4 days administration (on-day) and consecutive 3 days discontinuation (off-day) of PSL every week (intermittent period), keeping the weekly dose of PSL in the preceding daily regimen. In 2 patients (group II) with multiple myeloma and idiopathic thromocytopenic purpura, respectively, PSL was started with the intermittent regimen of PSL without preceding daily period. In group I, pharmacokinetic studies by respective oral and i.v. administrations of 40mg PSL and of 25.6mg PSL hemisuccinate (equivalent to 20mg of PSL) were performed before treatment, in daily period and both on on-day and off-day within the same week during intermittent period. In one patient of group II, study only by intravenous PSL administration was performed before treatment and in intermittent period. In another patient of group II, studies by oral and intravenous PSL administration were performed only in an intermittent period. PSL was measured by radioimmunoassay. Paired t-test was used for the comparison. In each case of group I, there was no difference in Cmax, Tmax, or AUCp.o. after oral administration of PSL among 4 periods tested, before treatment, daily period, on-day and off-day during intermittent period. On the intravenous PSL administration, increase in AUCi.v., prolongation of half-life, and decreases in MCR and bioavailability on on-day of intermittent period were observed in comparison with those before treatment, respectively. Only bioavailability among these parameters on on-day was increased compared with that in daily period. On the other hand, on off-day of intermittent period, decrease in AUCi.v. and increase in MCR were observed compared with those on on-day within the same week. When each parameter on off-day was compared with that of daily period, decrease in AUCi.v. and increases in MCR and bioavailability on off-day were observed. Vd did not differ each other among these 4 periods. Remarkable finding was the fact that MCR fluctuated regularly in 4 periods of this therapy regimen, i.e., significant decrease in daily period compared with before treatment, no significant difference between on-day and daily period, and the increase on off-day compared with that on on-day or in daily period.(ABSTRACT TRUNCATED AT 400 WORDS)
对10例接受泼尼松龙(PSL)长期间歇给药方案治疗的患者进行了药代动力学研究,给药方案为每周连续4天给药。8例患者(I组;3例肾病综合征、2例系统性红斑狼疮、以及各1例克罗恩病、大动脉炎综合征和溶血性贫血),PSL最初每日给药直至达到治疗效果(每日给药期),随后每周连续4天给药(服药日)和连续3天停药(停药日)(间歇期),保持前一每日给药方案中的每周PSL剂量。2例患者(II组)分别患有多发性骨髓瘤和特发性血小板减少性紫癜,PSL开始采用间歇给药方案,无前每日给药期。在I组中,在治疗前、每日给药期以及间歇期同一周内的服药日和停药日,分别通过口服和静脉注射40mg PSL以及25.6mg半琥珀酸PSL(相当于20mg PSL)进行药代动力学研究。II组的1例患者仅在治疗前和间歇期进行了静脉注射PSL的研究。II组的另1例患者仅在间歇期进行了口服和静脉注射PSL的研究。通过放射免疫测定法测定PSL。采用配对t检验进行比较。在I组的每种情况下,在测试的4个时期(治疗前、每日给药期、间歇期的服药日和停药日)口服PSL后,Cmax、Tmax或AUCp.o.均无差异。静脉注射PSL时,与治疗前相比,间歇期服药日的AUCi.v.增加、半衰期延长、MCR和生物利用度降低。在这些参数中,仅服药日的生物利用度与每日给药期相比有所增加。另一方面,在间歇期的停药日,与同一周内的服药日相比,AUCi.v.降低,MCR增加。当将停药日的每个参数与每日给药期的参数进行比较时,观察到停药日的AUCi.v.降低,MCR和生物利用度增加。这4个时期的Vd彼此无差异。显著的发现是,在该治疗方案的4个时期中,MCR有规律地波动,即与治疗前相比,每日给药期显著降低,服药日与每日给药期无显著差异,停药日与服药日或每日给药期相比增加。(摘要截断于400字)